| abstract |
REFERRING TO A COMPOUND DERIVED FROM CYCLOPENTAPYRIDINE AND TETRAHYDROQUINOLINE OF FORMULA (I), WHERE m IS 1 OR 2; n IS 0 O 1; L S -CHROa-; ROa IS H O C1-C4 ALKYL; R2 IS H O METHYL; R3 IS H, Cl, Br, F, CH3, and CN; R1 IS A GROUP OF FORMULA (1A), WHERE p, r AND s IS 0 O 1; R1a, R1b AND R1c IS F, I, CN, AMONG OTHERS. THE PREFERRED COMPOUNDS ARE: (7S) -7 - [(2,5-DIFLUOROBENZYL) OXI] -2-PIPERAZIN-1-IL-6,7-DIHYDRO-5H-CYCLOPENTA [b] PYRIDINE, (7S) -7- [ (3-FLUOROBENZYL) OXY] -2 - [(2R) -2-METHYLPIPERAZIN-1-IL] -6,7-DIHYDRO-5H-CYCLOPENTA [b] PYRIDINE, (7S) -7 - [(2-CHLOROBENZYL) OXI] -2 - [(2R) -2-METHYLPIPERAZIN-1-IL] -6,7-DIHYDRO-5H-CYCLOPENTA [b] PYRIDINE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE BINDERS OF THE 5-HT RECEPTOR, PARTICULARLY THEY ARE AGONISTS OF THE 5-HT2C RECEPTOR AND ARE USEFUL FOR THE TREATMENT OF OBESITY, PSYCHOSIS, AMONG OTHERS |